Retatrutide and Male Fertility: A Closer Look at What the Evidence Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Retatrutide is investigational. FormBlends does not sell or supply it. This article is educational, drawing on published GLP-1 class data.
• Direct human male fertility data for retatrutide has not been published.
• In the broader GLP-1 class, the dominant observed effect in men with obesity is weight-loss-mediated improvement in testosterone, sperm concentration, and motility.
• Direct drug-induced sperm toxicity has not been demonstrated in human studies of approved GLP-1 medications.
• The half-life of retatrutide is approximately 6 days; full pharmacologic washout takes roughly 4-5 weeks.

Direct answer

Retatrutide-specific human male fertility data have not been published. The closest relevant data come from the GLP-1 receptor agonist class, where men with obesity who lose substantial weight typically experience improvements in testosterone levels and sperm parameters. These improvements appear to be weight-loss-mediated rather than direct drug effects. For men actively trying to conceive, the practical question is usually about the timing of weight loss rather than a direct fertility hazard from the drug itself.

Table of contents

1. How obesity reduces male fertility
2. What the Phase 2 retatrutide trial recorded in men
3. The class effect: GLP-1 drugs and male reproductive markers
4. Testosterone, SHBG, and the obesity recovery pattern
5. Semen quality changes with weight loss
6. Animal data on GLP-1 receptor agonists in male reproduction
7. Erectile function and the vascular pathway
8. Sperm banking and the precautionary case
9. Contrary view: theoretical direct effects worth considering
10. Decision framework
11. FAQ
12. Sources

How obesity reduces male fertility

Male fertility is reduced in men with obesity through several converging mechanisms. Adipose tissue expresses aromatase, which converts testosterone to estradiol. Elevated estradiol suppresses pituitary gonadotropin secretion, reducing LH and FSH and lowering downstream testosterone production. The net effect is hypogonadotropic hypogonadism with low total testosterone, reduced free testosterone, and frequently impaired spermatogenesis.

Other contributing factors include insulin resistance (which lowers SHBG and alters androgen binding), elevated scrotal temperature from increased adipose mass, oxidative stress, and obstructive sleep apnea-related hormonal disturbance.

The relevant point: a man with obesity-related infertility has multiple potentially correctable contributors. Weight loss addresses several of them simultaneously.

What the Phase 2 retatrutide trial recorded in men

The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) enrolled both men and women with obesity. Sex-specific outcomes were not the focus, and the publication does not break out male reproductive endpoints. Reported safety endpoints include gastrointestinal AEs, hepatic enzyme changes, heart rate effects, and skin events.

Sperm parameter testing, hormone panels for gonadotropins, and male reproductive outcomes were not pre-specified or reported. This is standard for an obesity-trial Phase 2 program; reproductive endpoints typically appear in dedicated mechanistic studies or post-marketing investigations rather than primary efficacy trials.

The TRIUMPH Phase 3 program continues this structure. Reproductive outcomes are not the focus of the primary endpoints.

The class effect: GLP-1 drugs and male reproductive markers

Several published studies of approved GLP-1 medications in men with obesity-related hypogonadism have reported reproductive findings:

• A randomized trial of liraglutide in men with obesity and functional hypogonadism reported increases in total testosterone of approximately 1.5-2 nmol/L over 16 weeks alongside 5-7 kg weight loss (Jensterle et al.).
• An open-label study of semaglutide in men with obesity reported similar testosterone increases with substantially greater weight loss.
• Smaller studies have reported improvements in sperm concentration, motility, and total motile sperm count in men with obesity who lose weight, though the magnitude depends on baseline.

The pattern across these studies is that the magnitude of hormonal recovery correlates with the magnitude of weight loss. Drugs producing more weight loss appear to produce more reproductive marker improvement, which is consistent with a weight-mediated mechanism rather than a drug-specific effect.

Testosterone, SHBG, and the obesity recovery pattern

The typical recovery pattern in men with obesity-related hypogonadism includes:

Marker	Baseline in obesity	Direction with weight loss
Total testosterone	Low	Up
Free testosterone	Low or normal	Variable
SHBG	Low	Up
Estradiol	Often elevated	Down
LH and FSH	Inappropriately normal or low	Up
Sperm concentration	Variable, often reduced	Often up

This is the pattern of recovering hypothalamic-pituitary-gonadal axis function as adipose-driven suppression is relieved. The pattern is similar regardless of how the weight loss is achieved (lifestyle, bariatric surgery, or pharmacotherapy).

Semen quality changes with weight loss

Semen analysis is the standard measure of male fertility. The WHO 6th edition reference ranges define the lower limits of normal as approximately 16 million per mL for sperm concentration, 30 percent total motility, and 4 percent normal morphology.

Studies of weight loss in men with obesity report improvements in concentration and motility, with smaller and more variable effects on morphology. The magnitude depends on baseline values and the degree of weight loss.

For men with severely reduced sperm parameters at baseline, weight loss alone is rarely sufficient to restore fertility to normal. Combination approaches with urology evaluation, testosterone optimization (in selected cases), and assisted reproductive techniques may be needed.

Animal data on GLP-1 receptor agonists in male reproduction

The preclinical reproductive toxicology programs for approved GLP-1 receptor agonists include male fertility studies in rats and other species. Findings have generally been unremarkable at clinically relevant exposures, though some studies have noted dose-dependent effects on body weight that secondarily reduce testicular weight and sperm parameters at very high doses.

Eli Lilly has not published a detailed retatrutide male fertility preclinical data set. The class-wide pattern is reassuring but does not substitute for retatrutide-specific data.

Erectile function and the vascular pathway

Erectile dysfunction is highly prevalent in men with obesity, often through vascular mechanisms: endothelial dysfunction, atherosclerosis affecting penile arteries, and metabolic syndrome contributions.

Weight loss generally improves erectile function. Studies of approved GLP-1 medications report improvements in International Index of Erectile Function (IIEF) scores alongside weight loss in men with obesity. The mechanism is presumed to be vascular and hormonal rather than a direct drug effect.

Retatrutide-specific ED data has not been published.

Sperm banking and the precautionary case

For men considering medication during active conception attempts, sperm banking is a personal decision. The arguments in favor:

• Investigational drugs have less long-term reproductive outcome data than approved drugs.
• Sperm cryopreservation is relatively low-cost and well-established.
• The 4-5 week washout window after discontinuation may not be timing-compatible with conception goals.

Arguments against:

• No human male fertility hazard has been demonstrated for approved GLP-1 drugs.
• Weight loss typically improves rather than worsens male reproductive markers.
• Banking carries its own costs and emotional considerations.

A reproductive endocrinology consultation can frame the choice in the context of individual fertility goals and medical history.

Contrary view: theoretical direct effects worth considering

Some researchers have proposed theoretical mechanisms by which GLP-1 receptor agonists might affect testis function directly. GLP-1 receptors are expressed in testicular tissue at low levels, and animal studies have explored whether agonism affects Sertoli cell function or steroidogenesis. The findings are mixed and have not translated into clinically observable effects in human studies.

The intellectually honest position is that absence of evidence is not the same as evidence of absence. For a relatively new drug class without decades of post-marketing surveillance, theoretical direct effects on reproductive tissues cannot be excluded with high confidence. They have simply not been demonstrated.

For retatrutide specifically, with even less surveillance data, the same caveat applies more strongly.

Decision framework

If you are actively trying to conceive:

• Discuss timing of medication initiation with your clinician and partner. Weight-loss benefit may take time to manifest in reproductive markers.
• For approved GLP-1 drugs, no male discontinuation requirement exists in current labeling.

If you have obesity-related hypogonadism:

• Weight loss generally improves testosterone, gonadotropins, and sperm parameters.
• Endocrinology or reproductive endocrinology consultation is reasonable before adding testosterone therapy directly.

If you are considering sperm banking:

• Reasonable precaution if conception is planned but timing is uncertain.
• Not strictly indicated based on current evidence.

If you are a trial participant:

• Follow trial protocol guidance on conception planning.

Retatrutide status for this question

For Retatrutide and Male Fertility: A Closer Look at What the Evidence Actually Shows, the starting point is regulatory status: retatrutide remains investigational as of May 2026 and is not FDA-approved. FormBlends does not sell, prescribe, dispense, or supply retatrutide; the legitimate access path is clinical-trial participation.

This page is education about the evidence and safety boundaries for does, retatrutide, affect, male, fertility. It is not dosing, purchasing, mixing, or preparation guidance. If you need treatment now, ask a licensed clinician about approved options such as semaglutide or tirzepatide.

FAQ

Does retatrutide affect male fertility? No retatrutide-specific human data has been published. Class-effect reasoning suggests weight-loss-mediated improvement in reproductive markers is the dominant pattern.

Do GLP-1 drugs lower testosterone? No, the dominant pattern is improvement in testosterone with weight loss.

Do GLP-1 drugs improve sperm parameters? Small studies suggest improvement, mostly attributable to weight loss.

Should men trying to conceive avoid retatrutide? Retatrutide is investigational; access is trial-only. For approved GLP-1 drugs, no male discontinuation requirement exists.

What do animal studies say? Class-wide animal male fertility data is largely reassuring at clinically relevant exposures.

Can retatrutide cause ED? Direct ED induction has not been reported as a class pattern. Weight loss generally improves erectile function.

What is the washout period? Approximately 4-5 weeks based on the 6-day half-life.

Should I bank sperm? A personal decision. Reasonable as a precaution if conception is planned.

Is retatrutide FDA-approved? No. Retatrutide is investigational and not FDA-approved.

Related guides

• Survodutide for MASH: Boehringer's Dual Agonist, Closer Look
• Does Retatrutide Cause Infertility? What the Evidence Actually Supports
• Does Retatrutide Show Up on a Drug Test? What Standard Panels Actually Look For
• Does Retatrutide Affect Female Fertility? Reading the Signals That Exist
• Retatrutide and Fertility Impact
• Retatrutide for Pcos Fertility Improvement

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). NEJM. 2023;389:514-526.
2. Rosenstock J et al. Retatrutide in Type 2 Diabetes. The Lancet. 2023;402:529-544.
3. Jensterle M et al. Liraglutide for men with hypogonadism and obesity. European Journal of Endocrinology. 2019;181:583-592.
4. Calderon B et al. Effects of bariatric surgery on male obesity-associated hypogonadism. Obesity Surgery. 2014;24:1686-1692.
5. Hammoud AO et al. Impact of male obesity on infertility. Fertility and Sterility. 2008;90:897-904.
6. WHO laboratory manual for the examination and processing of human semen, 6th edition. World Health Organization. 2021.
7. Corona G et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review. European Journal of Endocrinology. 2013;168:829-843.
8. Endocrine Society Clinical Practice Guideline. Testosterone Therapy in Men with Hypogonadism. 2018.
9. Wegovy (semaglutide) prescribing information. Novo Nordisk. Revised 2024.
10. Zepbound (tirzepatide) prescribing information. Eli Lilly. Revised 2024.
11. ClinicalTrials.gov. TRIUMPH Program Records. Accessed May 2026.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384:989-1002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting patients with independent licensed clinicians and U.S.-licensed pharmacies. We do not manufacture, prescribe, or dispense medication.

Compounded Medication Notice. Compounded preparations are produced by 503A pharmacies for individual patients. They are not FDA-approved or reviewed through the FDA approval process and are not interchangeable with branded products. Retatrutide is not lawfully compoundable because it is investigational.

Results Disclaimer. Reproductive marker changes vary widely by individual. The patterns described here describe group averages from published studies, not individual predictions.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly. Retatrutide is an investigational compound from Eli Lilly. FormBlends has no affiliation with these companies.